Molecular effects of topoisomerase II inhibitors in AML cell lines: Correlation of apoptosis with topoisomerase II activity but not with DNA damage

Leukemia

Volumn 13, Issue 11, 1999, Pages 1859-1863

  Gieseler, F ^a   Bauer, E ^b   Nuessler, V ^c   Clark, M ^a   Valsamas, S ^b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Chemotherapy; DNA damage; Leukemia; Topoisomerase

Indexed keywords

ACLARUBICIN; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; PROTEIN P53;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; CANCER CELL CULTURE; CELL STRAIN HL 60; CONFERENCE PAPER; CORRELATION FUNCTION; DNA BINDING; DNA DAMAGE; DNA STRAND BREAKAGE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0032697584     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401570     Document Type: Conference Paper

References (32)

1. D'Incalci M. DNA-topoisomerase inhibitors. Curr Opin Oncol 1993; 5: 1023-1028.
2. Burden DA, Kingma PS, Froelich Ammon SJ, Bjornsti MA, Patchan MW, Thompson RB, Osheroff N. Topoisomerase II etoposide interactions direct the formation of drug-induced enzyrne-DNA cleavage complexes. J Biol Chem 1996; 271: 29238-29244.
3. Tewey KM, Rowe TC, Yang L, Halligen BD, Liu LF. Adriamycininduced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984; 226: 466-468.
4. Nishiyama M, Horichi N, Mazouzi Z, Bungo M, Saijo N, Tapiero H. Can cytotoxic activity of anthracyclines be related to DNA damage? Anticancer Drug Des, 1990; 5: 135-139.
5. Belvedere G, Suarato A, Geroni C, Giuliani FC, D'Incalci M. Comparison of intracellular drug retention, DNA damage and cytotoxicity of derivatives of doxorubicin and daunorubicin in a human colon adenocarcinoma cell line (LoVo). Biochem Pharmacol 1989; 38: 3713-3721.
6. de Tinguy-Moreaud E, Pourquier P, Montaudon D, Robert J. Relationships between DNA damage and growth inhibition induced by topoisomerase II-interfering drugs in doxorubicinsensitive and -resistant rat glioblastoma cells. Anticancer Res 1994; 14: 99-103.
7. Frieser C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/FAS) receptor/Iigand system in drug-induced apoptosis in leukemia cells. Nature Med 1996; 2: 574-577.
8. Ro̧thig H-J, Kraemer HP, Sedlacek HH. Aclarubicin: experimental and clinical experience. Drugs Exp Clin Res 1985; 11: 123-125.
9. Hilbe W, Thaler J, Eisterer W, Ludescher C, Niederwieser D. Treatment of relapsed and refractory acute myelogenous leukaemia with aclacinomycin A (ACA) and etoposide (VP-16). Leukemia Res 1994; 18: 655-658.
10. Harada M, Shibuya T, Teshima T, Murakawa M, Okamura T, Niho Y, Gondo H, Hayashi S, Akashi K, Tamura K et al. A randomized phase II trial of low-dose aclarubicin vs very low-dose cytosine arabinoside for treatment of myelodysplastic syndromes. Leukemia Res 1993; 17: 629-632.
11. Hansen OP, Pedersen BJ, Ellegaard I, Brincker H, Boesen AM, Christensen BE, Drivsholm A, Hippe E, Jans H, Jensen KB et al. Aclarubicin plus cytosine arabinoside vs daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark. Leukemia 1991; 5: 510-516.
12. Yamada K, Furusawa S, Saito K, Waga K, Koike T, Arimura H, Aoyagi A, Yamato H, Sakuma H, Tsunogake S et al. Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study. Leukemia 1995; 9: 10-14.
13. Perkins AS, Stern DF. Apoptosis. In: De Vita VT, Hellmann S, Rosenberg SA (eds). Cancer: Principles & Practice of Oncology, fifth edn. Lippincott-Raven: Philadelphia, 1997, pp 79-102.
14. Iijima N, Miyamura K, Itou T, Tanimoto M, Sobue R, Saito H. Functional expression of Fas (CD95) in acute myeloid leukemia cells in the context of CD34 and CD38 expression: possible correlation with sensitivity to chemotherapy. Blood 1997; 90: 4901-4909.
15. Eischen CM, Kottke TJ, Martins LM, Basi GS, Tung JS, Earnshaw WC, Leibson PJ, Kaufmann SH. Comparison of apoptosis in wildtype and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood 1997; 90: 935-943.
16. Clark M, Gieseler F. A method for the determination of topoisomerase II alpha and beta activity in patient cells. Proc AACR 1994; 34: 209.
17. Gieseler F, Glasmacher A, Kampfe D, Wandt H, Nuessler V, Valsamas S, Kunze J, Wilms K. Topoisomerase II activities in AML and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines. Leukemia 1996; 10: 1177-1180.
18. Solary E, Bertrand R, Pommier Y. Apoptosis induced by DNA topoisomerase I and II inhibitors in human leukemic HL-60 cells. Leuk Lymphoma 1994; 15: 21-32.
19. Nelson WG, Kastan MB. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 1994; 14: 1815-1823.
20. Gieseler F, Nüßler V, Brieden T, Kunze J, Valsamas S. Intracellular pharmacokinetics of anthracyclines in human leukemia cells: correlation of DNA-binding with apoptotic cell death, Int J Pharmacol 1998; 36: 25-28.
21. Danks MK, Qiu J, Catapano CV, Schmidt CA, Beck WT, Fernandes DJ. Subcellular distribution of the alpha and beta topoisomerase II-DNA complexes stabilized by VM-26. Biochem Pharmacol 1994; 48: 1785-1795.
22. Fernandes DJ, Danks MK, Beek WT. Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM-2b and m-AMSA. Biochemistry 1990; 29: 4235-4241.
23. Osheroff N. Biochemical basis for the interactions of type I and type II topoisomerases with DNA. Pharmacol Ther 1989; 41: 223-241.
24. Robinson MJ, Osheroff N. Effects of antioncoplastic drugs on the post-strand-passage DNA cleavage/religation equilibrium of topoisomerase II. Biochem 1991; 30: 1807-1831.
25. Olive PL, Johnston PJ, Banath JP, Durand RE. The comet assay: a new method to examine heterogeneity associated with solid tumors. Nature Med 1998; 4: 103-105.
26. McKelvey-Martin V, Green MH, Schmezer P, Pool ZB, De MM, Collins A. The single cell gel electrophoresis assay (comet assay): a European review. Mutat Res 1993; 288: 47-63.
27. Gille L, Nohl H. Analyses of the molecular mechanism of adriamycin-induced cardiotoxicity. Free Radic Biol Med 1997; 23: 775-782.
28. Hershko C, Link G, Tzahor M, Pinson A. The role of iron and iron chelators in anthracycline cardiotoxicity. Leuk Lymphoma 1993; 11: 207-214.
29. Monti E, Prosperi E, Supino R, Bottiroli G. Free radical-dependent DNA lesions are involved in the delayed cardiotoxicity induced by adriamycin in the rat. Anticancer Res 1995; 15: 193-197.
30. Wolf D, Rotter V. Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc Natl Acad Sci USA 1985; 82: 790-794.
31. Akashi M, Hachiya M, Osawa Y, Spirin K, Suzuki G, Koeffler HP. Irradiation induces WAF1 expression through a p53-independent pathway in KG-1 cells. J Biol Chem 1995; 270: 19181-19187.
32. McGahon AJ, Costa Pereira AP, Daly L, Cotter TG. Chemotherapeutic drug-induced apoptosis in human leukaemic cells is independent of the Fas (APO-1/CD95) receptor/ligand system. Br J Haematol 1998; 101: 539-547.